Month: April 2021

Valoe ja Sono Motors allekirjoittivat noin 2,2 miljoonan euron yhteistyösopimuksen

Written by Customer Service on April 19, 2021. Posted in Public Companies.

Valoe Oyj Sisäpiiritieto 19.4.2021 klo 09.55 Valoe Oyj ja Sono Motors GmbH ovat allekirjoittaneet noin 2,2 miljoonan euron yhteistyösopimuksen suunnittelu- ja teollistamisprojektista koskien aurinkoenergian hyödyntämistä Sono Motorsin ajoneuvoissa. Projekti alkaa heti ja kestää noin 12 kuukautta. Valoe palkkaa Juvan tehtaalle useita uusia työntekijöitä erilaisiin kehittämis- ja valmistustehtäviin. Mikkelissä 19. päivänä huhtikuuta 2021 Valoe Oyj HALLITUS Lisätietoja:Toimitusjohtaja Iikka Savisalo, Valoe Oyjp. 0405216082email: iikka.savisalo@valoe.com Jakelu:Nasdaq Helsinki OyKeskeiset tiedotusvälineetwww.valoe.com Valoen toimiala muodostuu uusiutuvaan energiaan, erityisesti aurinkosähköön, liittyvistä sovellutuksista. Valoe myy sen omaan teknologiaan pohjautuvaa automaattista aurinkosähkömoduulien valmistustekniikkaa,...

Lectra: Lectra shareholders’ vote on Gerber Technology acquisition project postponed

Written by Customer Service on April 19, 2021. Posted in Mergers And Acquisitions.

Lectra shareholders’ vote onGerber Technology acquisition project postponed Paris, April 19, 2021 – Lectra‘s shareholders’ vote on the proposed acquisition of Gerber Technology, initially scheduled for the April 30, 2021 Shareholders’ Meeting, has been postponed to June 1, 2021, as the decision of the American regulatory authority is now expected on May 27, 2021. A Shareholders’ Meeting will be convened on June 1, 2021 specifically for this purpose and a report containing the information on the agenda will be made available to the shareholders. The acquisition is expected to become final following the June 1, 2021 Shareholders’ Meeting, subject to approval by both the shareholders and the American regulatory authority. About Lectra For companies that breathe life into our wardrobes, car interiors, furniture and more, Lectra is crafting...

LECTRA : Report du vote des résolutions de l’assemblée générale liées au projet d’acquisition de Gerber Technology

Written by Customer Service on April 19, 2021. Posted in Mergers And Acquisitions.

Report du vote des résolutions de l’assemblée généraleliées au projet d’acquisition de Gerber Technology Paris, lundi 19 avril 2021 – Le vote des actionnaires de Lectra sur le projet d’acquisition de Gerber Technology, initialement prévu lors de l’assemblée générale annuelle du 30 avril 2021, est reporté au 1erjuin 2021, la décision de l’autorité américaine de la concurrence sur l’opération étant désormais attendue le 27 mai 2021. Une assemblée générale sera convoquée le 1er juin 2021 spécialement à cet effet et un rapport contenant les informations relatives aux résolutions sera mis à la disposition des actionnaires. L’acquisition devrait ainsi être réalisée à l’issue de l’Assemblée générale du 1er juin 2021, sous réserve d’un avis favorable de l’autorité réglementaire américaine et d’un vote favorable des actionnaires. A propos de Lectra...

Proactive news headlines including Rumble Resources, Elementos, Creso Pharma and Chalice Mining

Written by Customer Service on April 19, 2021. Posted in Mergers And Acquisitions.

Sydney, April 19, 2021 (GLOBE NEWSWIRE) — Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:Rumble Resources Ltd (ASX:RTR) has hit a new record after fast-tracked assay results from two reverse circulation (RC) holes at Chinook Prospect of the Earaheedy JV Project in Western Australia confirmed a zinc-lead discovery. Click here Elementos Limited (ASX:ELT) (OTCMKTS:ELTLF) (FRA:9EM) has received firm commitments from institutional, sophisticated and accredited investors to raise A$6.1 million through a placement to progress the development of its wholly-owned Oropesa Tin Project in Spain. Click here Creso Pharma Ltd’s (ASX:CPH) (FRA:1X8) target acquisition Halucencex Life Sciences Inc has signed a non-binding Letter of Intent (LOI) with leading...

Number of Shares and Voting Rights of Innate Pharma as of April 1, 2021

Written by Customer Service on April 19, 2021. Posted in Public Companies.

MARSEILLE, France, April 19, 2021 (GLOBE NEWSWIRE) — Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (the “Company” – Euronext Paris: FR0010331421 – IPH; Nasdaq: IPHA) releases its total number of shares outstanding as well as its voting rights as at April 1, 2021:Total number of shares outstanding: 78,996,240 ordinary shares 6,806 Preferred Shares 20167,581 Preferred Shares 2017Total number of theoretical voting rights (1):Total number of exercisable voting rights (2): 79,799,62179,781,046(1) The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance...

Celyad Oncology Appoints Dr. Charles Morris as Chief Medical Officer

Written by Customer Service on April 19, 2021. Posted in Public Companies.

MONT-SAINT-GUIBERT, Belgium, April 19, 2021 (GLOBE NEWSWIRE) — Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced the appointment of Dr. Charles Morris to the position of Chief Medical Officer. Dr. Morris will lead and provide strategic direction for all medical, regulatory and clinical development activities. “We are delighted to bring someone with Dr. Morris’s vast expertise and experience on board during this pivotal time in the Company,” said Filippo Petti, CEO of Celyad Oncology. “Dr. Morris has played an integral part in guiding multiple late-stage oncology drugs to approval and his demonstrated track record of leadership in the pharmaceutical industry will greatly benefit...

NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS OF APRIL 1, 2021

Written by Customer Service on April 19, 2021. Posted in Public Companies.

Marseille, France, April 19, 2021 (GLOBE NEWSWIRE) — Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (the “Company” – Euronext Paris: FR0010331421 – IPH; Nasdaq: IPHA) releases its total number of shares outstanding as well as its voting rights as at April 1, 2021:Total number of shares outstanding: 78,996,240 ordinary shares 6,806 Preferred Shares 2016 7,581 Preferred Shares 2017Total number of theoretical voting rights (1): Total number of exercisable voting rights (2):79,799,621 79,781,046(1) The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In...

NOUVEAU NOMBRE D’ACTIONS ET DE DROITS DE VOTE D’INNATE PHARMA AU 1ER AVRIL 2021

Written by Customer Service on April 19, 2021. Posted in Public Companies.

Marseille, France, 19 avr. 2021 (GLOBE NEWSWIRE) — Conformément aux articles L. 233-8 II du Code de Commerce et 223-16 du règlement général de l’Autorité des marchés financiers (l’« AMF »), Innate Pharma SA (la « Société » – Euronext Paris : FR0010331421 – IPH ; Nasdaq : IPHA) publie le nombre d’actions composant son capital social ainsi que le nombre de droits de vote associés au 1er avril 2021 : Nombre d’actions composant le capital : 78 996 240 actions ordinaires 6 806 Actions de Préférence 2016 7 581 Actions de Préférence 2017Nombre de droits de vote théoriques (1) : Nombre de droits de vote exerçables (2) : 79 799 621 79 781 046(1) Le nombre de droits de vote théoriques (ou droits de vote « bruts ») sert de...

Q1 sales up 12.2% on an organic basis, in all regions strong outperformance, full-year financial targets confirmed

Written by Customer Service on April 19, 2021. Posted in Public Companies.

Nanterre (France), April 19, 2021 FIRST-QUARTER 2021 SALES Q1 2021 SALES UP 12.2% ON AN ORGANIC BASIS IN ALL REGIONS, STRONG OUTPERFORMANCE FULL-YEAR FINANCIAL TARGETS CONFIRMEDIn €m Q1 2020* Q1 2021 ChangeGroup sales 3,678 4,005 +8.9%At constant scope and currencies +12.2%* Q1 2020 sales restated for IFRS 5 (see in Appendix) Q1 SALES UP 12.2% ON AN ORGANIC BASIS, WITH STRONG OUTPERFORMANCE IN ALL REGIONSDouble-digit organic growth for Seating, Interiors and Clean Mobility; organic growth of 5.7% for Clarion Electronics, despite the shortage of electronic components In all regions, strong outperformance, with sales in China exceeding pre-Covid sales of Q1 2019 At Group level, Q1 sales performance continued to be impacted by a significant unfavorable geographic mix effect estimated at c. 900bps Turnaround of this geographic...

Croissance organique des ventes au T1 de +12,2%, forte superformance dans toutes les régions, objectifs financiers confirmés pour l’ensemble de l’exercice

Written by Customer Service on April 19, 2021. Posted in Public Companies.

Nanterre (France), le 19 avril 2021 VENTES DU PREMIER TRIMESTRE 2021 CROISSANCE ORGANIQUE DES VENTES AU T1 DE +12,2% FORTE SURPERFORMANCE DANS TOUTES LES REGIONS OBJECTIFS FINANCIERS CONFIRMÉS POUR L’ENSEMBLE DE L’EXERCICEen M€ T1 2020* T1 2021 VariationVentes du Groupe 3 678 4 005 +8,9 %à périmètre et taux de change constants +12,2 %* Ventes du T1 2020 retraitées IFRS 5 (cf. annexe) CROISSANCE ORGANIQUE DE 12,2% DES VENTES AU T1 ET FORTE SURPERFORMANCE DANS TOUTES LES REGIONSCroissance organique à deux chiffres pour les activités Seating, Interiors et Clean Mobility ; croissance organique de 5,7% pour Clarion Electronics, malgré la pénurie de composants électroniques Forte surperformance dans toutes les régions, avec des ventes en Chine qui ont dépassé les ventes pré-Covid du T1 2019 Au niveau du Groupe, la performance...

Month: April 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals